Human salivary glands secrete 1000-1500 ml per day of saliva composed of water, proteins and low molecular mass substances (mainly electrolytes). Up to 26% of the salivary proteins are mucins [1] . The mucins of human saliva are extremely effective lubricants, which provide an effective barrier against desiccation and environmental insult. They control permeability of mucosal surface, limit penetration of potential irritants and toxins to mucous cells, protect mucosal cell membranes against proteases generated by bacteries in the bacterial plaques around the teeth and regulate colonization of the oral cavity by bacteria and viruses [2] . The mucins are high molecular mass glycoproteins [3, 4] , in which proline and serine/threonine constitute up to 20-55% of total amino acids and are concentrated in one or several regions of the polypeptide. These serine/threonine residues are heavily glycosylated, and 40-80% of the mass of such mucins consists of O-linked oligosaccharides [5] . The cysteines at the N-and C-ends may link mucin monomers by disulfide bridges forming linear mucin oligomers [6] . 
Human salivary glands secrete 1000-1500 ml per day of saliva composed of water, proteins and low molecular mass substances (mainly electrolytes). Up to 26% of the salivary proteins are mucins [1] . The mucins of human saliva are extremely effective lubricants, which provide an effective barrier against desiccation and environmental insult. They control permeability of mucosal surface, limit penetration of potential irritants and toxins to mucous cells, protect mucosal cell membranes against proteases generated by bacteries in the bacterial plaques around the teeth and regulate colonization of the oral cavity by bacteria and viruses [2] . The mucins are high molecular mass glycoproteins [3, 4] , in which proline and serine/threonine constitute up to 20-55% of total amino acids and are concentrated in one or several regions of the polypeptide. These serine/threonine residues are heavily glycosylated, and 40-80% of the mass of such mucins consists of O-linked oligosaccharides [5] . The cysteines at the N-and C-ends may link mucin monomers by disulfide bridges forming linear mucin oligomers [6] . Two types of mucins are present in human sa- liva: oligomeric mucin glycoprotein (MG1) with molecular mass above 1 MDa, and monomeric mucin glycoprotein (MG2) with molecular mass of 200-250 kDa [1] . The submandibulary glands containing mucous cells (producing MG1) and serous cells (producing MG2) secrete 30% of the salivary mucins, while sublingual, labial and palatal glands (which contain mainly mucous cells) secrete 70% [7] [8] [9] [10] [11] . Concentration of mucin secreted by sublingual glands is higher than that secreted by submandibulary glands, while the secretion of parotid glands is devoid of mucins [7, 12] .
POLYPEPTIDES OF SALIVARY MUCINS
Three genes encoding mucins in human salivary glands have been reported [5] : MUC1 localized to chromosome 1q21-24, which encodes a transmembrane mucin [13] , and two genes encoding secretory mucins, MUC5B localized to chromosome 11p15.5 encoding oligomeric mucin (MG1) [7] and MUC7 localized to chromosome 4q13-21 encoding monomeric MG2 [13] . The limited expression of MUC5B in sublingual and submandibulary glands secreting huge amounts of oligomeric mucins suggests that MG1 is encoded by two or more mucin genes [10] . The peptide sequence of MG1, deduced from the nucleotide sequence of the MUC5B gene, consists of about 5000 amino acids grouped in three domains: N-terminal, central and C-terminal [10] (Fig. 1A) . It is suggested that the N-terminal domain of MUC5B gene product comprising about 450 amino acids is cysteine-rich and contains potential N-glycosylation sites [10] . A single large exon encoding the central domain of MG1 comprising 3570 amino acids (rich in threonine (27%), serine (12.9%) and proline (10.6%)) has been described. The domain consists of 19 subdomains: seven cysteine-rich, 3 subdomains with no repeats, 5 irregular tandem repeats and 4 unique R-end sequences conserved over a long evolutionary time scale, with no typical repeats. Disulfide bridges and hydrophobic sites possessing negatively charged amino acids of the central domain of MG1 occupy seven cysteine-rich subdomains (Cys1-Cys7) rich in cysteine (70 residues), aspartic acid (37 residues) and glutamic acid (58 residues). Cysteine-rich subdomains contain also a large number of aromatic amino acids, i.e., tyrosine (31 residues), phenylalanine (31 residues) and tryptophan (17 residues) [13] . Two laboratories reported that the C-terminal domain of MG1 comprises 804 [10] or 808 [17] amino acids, respectively. It is relatively rich in cysteine and proline, but relatively poor in threonine and serine [10, 17] and has a similar structure to von Willebrand factor (vWF) [19] . Based on the similarity to this factor was encoded six subdomains in the C-terminal domain of MG1 ( Fig. 1C (Fig. 5) 
BIOSYNTHESIS OF SALIVARY MUCINS OLIGOSACCHARIDES
The biosynthesis and processing of the N-linked glycoproteins is now almost completely understood [14] . It has been shown that although low molecular mass rat submandibular mucin is N-glycosylated, this N-glycosylation is not required for its secretion [31] . Recently, however, it has been reported that some mucins, e.g. N-glycosylated human colonic mucin (MUC2), become associated with the lectin-like chaperones (calreticulin and calnexin) by disulfide bridges, before folding to their correct structure in the ER [32] . There is no data available on such chaperone action on MG1 or MG2. Recently new information concerning O-glycosylation appeared [14] . Most studies indicate that O-glycosylation is initiated in the cis Golgi compartment. Glycosyltransferases can be divided into two types: those transferring the sugar residue with retention of its anomeric configuration, and those transferring with inversion. Both types of glycosyltransferases have similar nucleotide recognition domains [33] . The biosynthesis of O-linked glycans begins with addition of GalNAc to serine or threonine residues in a polypeptide chain [34] , catalysed by a family (6 members reported to the end of 1999 [35] ) of GalNAc polypeptide transferases (UDPGalNAc : polypeptide N-acetyl-galactosaminyltransferases, GalNAcT (EC 2.4.1.41)), which are conserved in evolution from nematodes to humans [36] . These GalNAc polypeptide transferases consist of short N-terminal cytoplasmic tails, transmembrane domains, extended stem regions and a large carboxyl terminal where the catalytic domains are located and which face the interior of the Golgi compartment [37] [38] [39] . Genes for GalNAc1T, -T2 and -T3 are localized to chromosomes 18q12-q21, 1q412-q42, and 2q24-q31, respectively [40] . This family of GalNAc polypeptide transferases has different expression patterns in different organs. The specificity for folded polypeptide chains of proteins and thus potential sites of O-glycosylation are different for each transferase [41] . Glycosylation of certain acceptor sites by one of the GalNAc polypeptide transferases is required before other sites can Vol. 47 Human salivary mucinsbe glycosylated by another GalNAc polypeptide transferase [31, 35] . In addition, individual GalNAc polypeptide transferases show different localization within the Golgi compartments [39] , moreover, the sizes of their stem regions are different [36] . The repertoire of GalNAc polypeptide transferases varies with cell localization and differentiation [42] . GalNAcT3 is expressed in all layers of normal human mouth epithelia and in most squamous carcinoma cells, GalNAcT2 was found in undifferentiated cell layers in the normal epithelial and in most carcinoma cells except in well differentiated foci. GalNAcT1 shows a low level of expression, markedly enhanced in tumors [42] . Positions C3 and C6 of the core GalNAc may be substituted by Gal, GalNAc, GlcNAc or NeuAc (Fig. 3 ) and thus create cores 1-8 [14] . Addition of each sugar to the O-linked GalNAc is catalysed by a specific transferase [43] . Much attention is devoted to a family of GlcNAc transferases (UDP-GlcNAc : Galb1-3-GalNAca1-R b1-6GlcNAc transferase) that take part in the synthesis of cores 2, 3 and 6.
Introduction of the C2GnT gene (encoding core 2 b1-6 acetylglucosaminyltransferase) to human pancreatic cancer cells shifts O-glycosylation toward more complex glycans [44] . It was reported that sialyl-and Gal-transferases compete with C2Gn transferase for the OH group at C6 of O-linked GalNAc. Activation of T cells results in induction of C2Gn transferase, which causes a shift of O-linked oligosaccharide chains from tetrasaccharide (NeuAc a2-3Galb1-3 (NeuAca2-6) GalNAc a1Ser/Thr) to hexasaccharide (NeuAc a2-3Gal b1-3 (NeuNAc a2-3 Gal b1-4GlcNAc b1-6) GalNAca1Ser/Thr) [45] . This C2GnT was expressed in 7 day embryos. In older embryos expression of C2GnT was restricted to the tissues producing mucins and cartilage [46] . P-Selectin glycoprotein ligand 1, a mucin type cell surface glycoprotein has been reported to be a substrate for C2Gn transferase [47] . Another member of C1-6 GlcNAc transferase family is I branching enzyme (IGnT) which transfers GlcNAc to C6 of galactose moiety in backbone structures (Fig. 4) . The activity of IGnT is associated with embryo- 
CONCLUSIONS AND FUTURE PROSPECTS
There is a consensus concerning the structure of the central and C-terminal regions of MG1. Soon we may expect a report on the N-terminal sequence of MG1. Also there is an agreement concerning the deduced sequence for MG2. Thirty seven O-linked oligosaccharide chains in MG1 and 41 in MG2 have been described, however, not all data on this subject are unanimous. There is a lack of consensus on the quantity and quality of oligosaccharide chains in human salivary mucins. Initiation of O-glycosylation takes place in the cis Golgi compartment, however, the subregions of Golgi where particular glycosylation steps take place are not yet known. The requirements of the tertiary structure of the substrates for particular glycosyltransferase action and eventual role of chaperones in this process are also not known. Rules have to be established for the competition of glycosyltransferases for a particular substrate. The number of mucin genes taking part in biosynthesis of the MG1 polypeptide chains remains to be established. Data indicating which potential O-and N-glycosylation sites are glycosylated and what is the nature of regulatory factors are urgently awaited. The source of the microheterogeneity of the oligosacharide chains of human salivary mucins is unknown. Regulation of the biosynthesis of the polypeptide and oligosaccharide chains and the changes taking place in pathological Vol. 47 Human salivary mucins 1075 
